Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996038166 - SERUM AMYLOID A PROTEIN

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. A method of potentiating the release and collection of cholesterol from inflammatory or atherosclerotic sites in vo-comprising: administering to a patient an effective amoimt of a composition comprising a compound selected from the group consisting of native serum amyloid A (SAA) and a ligand having SAA properties thereby increasing the affinity of high density lipoprotein (HDL) for macrophages and potentiating release and collection of cholesterol.

2. The method of claim 1 , wherein the compound is a ligand having SAA properties.

3. The method of claim 2, wherein the ligand is a non-amyloidogenic peptide derived from SAA.

4. The method of claim 1, wherein the native SAA is non-amyloidogenic.

5. A method of potentiating the release and collection of cholesterol from inflammatory or atherosclerotic sites in. vivo comprising: administering to a subject a nucleic acid construct encoding a peptide selected from the group consisting of SAA and a ligand having SAA properties, under conditions wherein said construct is incorporated into cells of said subject and said peptide is expressed in said subject, thereby increasing the affinity of high density lipoprotein (HDL) for macrophages and potentiating release and collection of cholesterol .

6. The method of claim 5, wherein the nucleic acid construct encodes a ligand having SAA properties.

7. The method of claim 6, wherein the ligand is non-amyloidogenic.

8. The method of claim 5, wherein the nucleic acid construct encodes a native SAA which is non-amyloidogenic.

9. The method of claim 5, wherein the nucleic acid construct is administered in a viral vector.

10 The method of claim 5, wherein the nucleic acid construct is administered in a non- viral gene delivery system.

l A method of reversing an atherosclerotic condition, comprising administering to a patient in need thereof an effective amount of a composition comprising a compound selected from the group consisting of native serum amyloid A (SAA) and a ligand having SAA properties, thereby increasing the affinity of high density lipoprotein (HDL) for macrophages and potentiating release and collection of cholesterol, such that an atherosclerotic condition is reversed.

12. The method of claim 11, wherein the compound is a ligand having SAA properties.

13. The method of claim 12, wherein the ligand is a non-amyloidogenic peptide derived from SAA.

14. The method of claim 11, wherein the native SAA is non-amyloidogenic.

15. A pharmaceutical composition, comprising a nucleic acid construct encoding a peptide selected from the group consisting of SAA and a ligand having SAA properties, in a pharmaceutically acceptable carrier.

16. The method of claim 15, wherein the peptide is a ligand having SAA properties.

17. The method of claim 16, wherein the ligand is a non-amyloidogenic peptide derived from SAA.

18. The method of claim 15, wherein the native SAA is non-amyloidogenic. .